Stay updated with breaking news from Trappsol Cyclo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maxim Group cut shares of Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Monday, The Fly reports. Cyclo Therapeutics Price Performance Shares of CYTH stock opened at $0.92 on Monday. The stock has a market cap of $9.71 million, a P/E […]
09.01.2023 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1
18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1
16.08.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ...
The Niemann-Pick Type C disease market is expected to grow from $128.35m last year to $188.35m in 2031 across the 3MM.